

What ACA's Uncertain Future Means for Biologics Patents

PUBLICATIONS | LESS THAN 1 MIN READ

February 27, 2020


By: Ted Mathias and Rebecca Clegg

Law360


Axinn partner Ted Mathias and associate Rebecca Clegg authored the *Law360* article, "What ACA's Uncertain Future Means for Biologics Patents."

Click [here](#) to access the article. A subscription is required.

Related People



Ted Mathias



Rebecca L. Clegg

To subscribe to our publications, [click here](#).

Featured Insights

- American Bar Association 2025 Asia-Pacific Conference
SPEAKING ENGAGEMENT ANTITRUST
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference
SPONSORSHIP ANTITRUST
- GCR Live: Law Leaders Global 2025
SPEAKING ENGAGEMENT ANTITRUST
- The 32nd Annual Marketing Partner Forum
EVENT
- SABA North America Corporate Counsel Retreat 2025
SPONSORSHIP ANTITRUST
- Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025
CLIENT ALERTS ANTITRUST
- Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards
AWARDS & RECOGNITIONS ANTITRUST
- Merger Remedies Back in Vogue Under Trump
MEDIA MENTIONS ANTITRUST
- Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation
AXINN VIEWPOINTS INTELLECTUAL PROPERTY
- A POSA's Motivation Is Not Required To Be the Same as the Inventor's in Evaluating Obviousness
AXINN VIEWPOINTS INTELLECTUAL PROPERTY

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved